Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorQilu Hospital of Shandong University
About this trial
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).
The main questions it aims to answer are:
Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.
Participants will:
Provide retrospective clinical, pathological, and metabolic data from hospital records.
Have survival and recurrence outcomes assessed through follow-up data review.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.
Disqualifiers
Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.
Trial population
The study population comprised adult patients (≥18 years) diagnosed with pancreatic neuroendocrine tumors (PanNETs) between 2013 and 2024. All cases had a histopathologically confirmed diagnosis and received treatment at one of the participating centers. Patients were excluded if they had poorly differentiated neuroendocrine carcinoma, mixed neuroendocrine-non-neuroendocrine neoplasm, undefined tumor differentiation, recurrent disease, non-initial treatment, or a history of other malignancies.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
600 Participants
are grouped into 2 trial groupsGroup A: Early-onset pancreatic neuroendocrine tumors group
Group B: Late-onset pancreatic neuroendocrine tumors group
Trial outcomes
Primary outcomes
1
Overall Survival
Time frame
From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 yearsSecondary outcomes
1
Disease-specific survival
Time frame
From date of diagnosis until death due to PanNETs, up to 12 years2
Progression-free survival
Time frame
From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.3
Disease-free survival
Time frame
From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Qilu Hospital of Shandong University
Lead sponsor
China-Japan Friendship Hospital
Collaborator
The Affiliated Hospital of Qingdao University
Collaborator
Qianfoshan Hospital
Collaborator
Source ClinicalTrials.gov